Skip to main content
Caplight Logo









NeuroPro Therapeutics

NeuroPro Therapeutics

Private
OregonHealthcare & Life Scienceshttps://neuropro.io/

Last Round

Early Funding

Mar 1, 2024

Total Funding Raised

$38M

Company Overview

NeuroPro Therapeutics is a biotechnology company that develops proprietary small molecule compounds to treat neurological diseases, including epilepsy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryclinical trialsepilepsy treatmentneurological disorderssmall-molecule drugbiopharmarefractory epilepsytherapeutic developmentmedicinal chemistryinvestigational drugpreclinical researchneurosciencedrug pipelinepharmaceutical R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuroPro Therapeutics Comparables

Compare NeuroPro Therapeutics with similar companies based on industry and business-model similarity.

NeuroPro Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IAMA Therapeutics
77%
Ovid Therapeutics Inc.
77%
EpilepsyGTx
75%

NeuroPro Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMar 1, 2024
Early FundingFeb 1, 2023

NeuroPro Therapeutics Investors

Notable investors and investment history

NeuroPro Therapeutics investors
InvestorRounds
Fengate Asset ManagementEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 69% MoM, reaching 3.2K.

  • Jan 20, 2026

    Monthly visitors grew 150% MoM, reaching 1.7K.

NeuroPro Therapeutics Filings

Explore SEC and related filing metadata, where available.

NeuroPro Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NeuroPro Therapeutics's valuation, stock price, and market status.

Is NeuroPro Therapeutics a public or private company?

NeuroPro Therapeutics is a private company.

What is the current stock price of NeuroPro Therapeutics?

NeuroPro Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NeuroPro Therapeutics worth (valuation)?

Valuation information for NeuroPro Therapeutics is not publicly available.

Can I buy NeuroPro Therapeutics stock?

NeuroPro Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NeuroPro Therapeutics's last funding round?

NeuroPro Therapeutics's most recent funding round was Early Funding on March 1, 2024.

Who are the main investors in NeuroPro Therapeutics?

Key investors in NeuroPro Therapeutics include Fengate Asset Management.

Will NeuroPro Therapeutics IPO soon?

No public IPO plans have been announced for NeuroPro Therapeutics.

How can I track NeuroPro Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NeuroPro Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOregon
Employee Range1
Year Founded2014
Last FundingMar 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?